ImageneBio Charts New Course Following Merger Completion

The corporate transformation of Ikena Oncology into ImageneBio has reached a significant administrative milestone with the recent submission of regulatory paperwork to the U.S. Securities and Exchange Commission. The filing of Form 4 documents formally establishes the ownership framework of the combined entity resulting from its merger with Inmagene Biopharmaceuticals.

These latest SEC submissions detail the exchange of preferred shares from the former Inmagene for common stock in the newly formed company. This transaction represents the final implementation of the merger agreement that received shareholder approval and was officially concluded on July 25, 2025.

The corporate overhaul encompasses multiple simultaneous developments:
* Implementation of a 1:12 reverse stock split in late July 2025
* Transition to trading under the fresh ticker symbol “IMA” starting July... Read more...